Rachael L DiSantostefano1, David Hinds2, Hoa Van Le3, Neil C Barnes4. 1. Worldwide Epidemiology, GSK, 5 Moore Drive, Research Triangle Park, NC 27709, USA. 2. Worldwide Epidemiology, GSK, 1250 South Collegeville Road, Collegeville, PA 19426, USA. Electronic address: David.R.Hinds@gsk.com. 3. Worldwide Epidemiology, GSK, 5 Moore Drive, Research Triangle Park, NC 27709, USA; PAREXEL International, Research Triangle Park, Durham, NC 27713, USA. 4. Respiratory Research & Development, GSK, Stockley Park, Uxbridge, Middlesex, UB11 1BT, UK; William Harvey Institute, Barts and the London School of Medicine and Dentistry, John Vane Building, Charterhouse Square, London, EC1M 6BQ, UK.
Abstract
BACKGROUND: Current evidence suggests that blood eosinophil levels (Eos) are associated with chronic obstructive pulmonary disease (COPD) treatment response and natural history. This analysis investigated the relationship between Eos levels and clinical characteristics in a representative cohort of US subjects with spirometry-defined COPD. METHODS: Cross-sectional data from the National Health And Nutrition Examination Survey (NHANES 2007-2010) of subjects ≥ 40 years with spirometry-defined COPD and Eos data (n = 948) were analyzed. Differences in clinical characteristics by Eos level (≤ 2%, > 2%) were compared using chi-square tests. Characteristics associated with Eos > 2% were identified using multivariate logistic regression modeling. Characteristics associated with Eos >2% among subjects with normal lung function, plus other cut-points among the COPD population, were evaluated post hoc. FINDINGS: Most participants had Eos >2%; 70.7% with spirometry-defined COPD and 65.5% with normal lung function. Older age, male gender, and severe current asthma were significantly associated with Eos >2% in COPD subjects. The Eos ≤ 2% COPD group had higher reported rates of previous heart attack and anemia. Among participants with normal lung function, Eos > 2% was associated with being male, being overweight/obese, older age, hay fever, and congestive heart failure. INTERPRETATION: In this large US-based cohort, Eos > 2% was prevalent in participants with COPD and normal lung function. Among participants with COPD, Eos > 2% was associated with specific characteristics including lower rates of some co-morbidities; however, the clinical implications and relationships between Eos levels, COPD mechanisms, and risk of outcomes require further evaluation.
BACKGROUND: Current evidence suggests that blood eosinophil levels (Eos) are associated with chronic obstructive pulmonary disease (COPD) treatment response and natural history. This analysis investigated the relationship between Eos levels and clinical characteristics in a representative cohort of US subjects with spirometry-defined COPD. METHODS: Cross-sectional data from the National Health And Nutrition Examination Survey (NHANES 2007-2010) of subjects ≥ 40 years with spirometry-defined COPD and Eos data (n = 948) were analyzed. Differences in clinical characteristics by Eos level (≤ 2%, > 2%) were compared using chi-square tests. Characteristics associated with Eos > 2% were identified using multivariate logistic regression modeling. Characteristics associated with Eos >2% among subjects with normal lung function, plus other cut-points among the COPD population, were evaluated post hoc. FINDINGS: Most participants had Eos >2%; 70.7% with spirometry-defined COPD and 65.5% with normal lung function. Older age, male gender, and severe current asthma were significantly associated with Eos >2% in COPD subjects. The Eos ≤ 2% COPD group had higher reported rates of previous heart attack and anemia. Among participants with normal lung function, Eos > 2% was associated with being male, being overweight/obese, older age, hay fever, and congestive heart failure. INTERPRETATION: In this large US-based cohort, Eos > 2% was prevalent in participants with COPD and normal lung function. Among participants with COPD, Eos > 2% was associated with specific characteristics including lower rates of some co-morbidities; however, the clinical implications and relationships between Eos levels, COPD mechanisms, and risk of outcomes require further evaluation.
Authors: Byron Thomashow; James D Crapo; M Bradley Drummond; MeiLan K Han; Ravi Kalhan; Elisha Malanga; Vinny Malanga; David M Mannino; Stephen Rennard; Frank C Sciurba; Kristen S Willard; Robert Wise; Barbara Yawn Journal: Chronic Obstr Pulm Dis Date: 2019-07-24
Authors: Jeffery Ho; Wajia He; Matthew T V Chan; Gary Tse; Tong Liu; Sunny H Wong; Czarina C H Leung; Wai T Wong; Sharon Tsang; Lin Zhang; Rose Y P Chan; Tony Gin; Joseph Leung; Benson W M Lau; William K K Wu; Shirley P C Ngai Journal: Sci Rep Date: 2017-10-18 Impact factor: 4.379
Authors: Jin Hwa Song; Chang-Hoon Lee; Jin Woo Kim; Won-Yeon Lee; Ji Ye Jung; Joo Hun Park; Ki Suck Jung; Kwang Ha Yoo; Yong Bum Park; Deog Keom Kim Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-08-17